分群 vs 药灵通AI
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
分群
Read full descriptionHide full description
洞察人群客流,帮助门店在进店、成交和客单等经营环节创收,并有效控制收银损耗,增效降本。 分群数据以分群创造价值为经营理念,致力于构建以客群为中心的零售新生态,让零售回归实体,彻底改变线下门店生意难做的局面。
药灵通AI
Read full descriptionHide full description
药灵通AI 是一款专为多家连锁药店打造的药品问询与经营辅助类工具型 APP。 功能:支持药店使用人员通过描述顾客症状、需求,快速精准推荐适配药品方案,同步提供药品适应症、用法用量、禁忌等专业信息,帮助连锁药店提升店员经营效率、提高服务专业度。 信息来源说明: 本应用中的药品信息来自国家药监局(NMPA)数据库、药品说明书及公开行业标准参考资料。所有信息均为公开可查的官方资料。 免责声明: 本应用仅提供药品相关的公开信息供药店人员内部学习与参考使用。 本应用不提供任何处方药推荐、诊断或治疗建议。 用户应在做出任何健康或用药决策前,咨询医生或其他合格的医疗专业人员。
Screenshots
Verdict
The clearest difference is iOS requirement: 分群 at 12.0 against 药灵通AI's 15.0. On price, update cadence, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
分群 ships an update fortnightly, 药灵通AI every 2 weeks. The most recent releases landed on September 17, 2026 and September 21, 2026 respectively.
| Parameter | 分群 | 药灵通AI |
|---|---|---|
| Price | Free | Free |
| Update frequency | Fortnightly — better | Every 2 weeks |
| Ads | No | No |
| In-app purchases | No | No |
| Devices | iPhone, iPod | iPhone, iPod |
| Requires iOS | 12.0 — better | 15.0 |
| Further details — not scored | ||
| Size | 118 MB | 9 MB |
| Age rating | 4+ | 17+ |
| Developer | 长沙分群大数据有限公司 | 药灵通AI |
In-app purchases
分群
No in-app purchases
药灵通AI
No in-app purchases









